Recent clinical reports of stereotactic ablative radiotherapy (SABR) in the treatment of low-risk prostate cancer have been encouraging. Our study evaluates the efficacy and safety of SABR using the CyberKnife system for treating intermediate- to very-high-risk prostate cancer.
Methods and Study Design
Between May 2010 and June 2013, 31 patients (15 intermediate risk, 14 high risk, and 2 very high risk) without pelvic lymph node metastasis were enrolled retrospectively. The treatment consisted of 37.5 Gy in 5 fractions over 1-2 weeks using CyberKnife SABR. Twenty-five patients (81%) received androgen deprivation therapy (ADT). Biochemical failure was defined using the nadir + 2 criterion. Toxicity was assessed with the Common Terminology Criteria of Adverse Events (version 4).
Results
The median follow-up was 36 months (range 7-58 months). The median pretreatment prostate-pecific antigen (PSA) was 13.5 ng/mL (range 4.5-124.0 ng/mL). The median PSA decreased to 0.09 ng/mL (range <0.04-5.38 ng/mL) and 0.12 ng/mL (range <0.04-2.63 ng/mL) at 6 months and 12 months after SABR, respectively. The 3-year biochemical relapse-free survival was 90.2% for all patients, 100% for the intermediate-risk patients, and 82% for the high- and very-high-risk patients (p = 0.186). No patient experienced ≥ grade 3 toxicity. There were 7 acute and 5 late grade 2 genitourinary toxicities and 1 acute and no late grade 2 gastrointestinal toxicity.
Conclusions
Our preliminary results support that CyberKnife SABR with ADT is safe and feasible in patients with intermediate- to high-risk prostate cancer. A further large-scale clinical trial with longer follow-up is warranted.
Get full access to this article
View all access options for this article.
References
1.
SiegelRMaJZouZJemalACancer statistics, 2014. CA Cancer J Clin2014;64 (1):9–29
2.
D'AmicoAVWhittingtonRMalkowiczSBBiochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998;280 (11):969–974
3.
KupelianPAPottersLKhuntiaDRadical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys2004;58 (1):25–33
4.
BuyyounouskiMKPriceRAJrHarrisEEStereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys2010;76 (5):1297–1304
5.
CeylanCKucukNBas AyataHGudenMEnginKDosimetric and physical comparison of IMRT and CyberKnife plans in the treatment of localized prostate cancer. Rep Pract Oncol Radiother2010;15 (6):181–189
6.
MacDougallNDDeanCMuirheadRStereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than CyberKnife?Clin Oncol2014;26 (1):4–9
7.
LinYWLinKHHoHWTreatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: non-isocentric CyberKnife versus isocentric RapidArc. Phys Med2014;30 (6):654–661
8.
GibbsICFrameless image-guided intracranial and extracranial radiosurgery using the Cyberknife robotic system. Cancer Radiother2006;10 (5):283–287
9.
FreemanDEKingCRStereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol2011;6 (1):3
10.
KatzAJSantoroMDiblasioFAshleyRStereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol2013;8 (1):118
11.
KingCRBrooksJDGillHPrestiJCJrLong-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys2012;82 (2):877–882
12.
BrennerDJMartinezAAEdmundsonGKMitchellCThamesHDArmourEPDirect evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys2002;52 (1):6–13
13.
MiralbellRRobertsSAZubizarretaEHendryJHDose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys2012;82 (1):e17–e24
14.
RoachMIIIHanksGThamesHJrDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006;65 (4):965–974
15.
KangJKChoCKChoiCWImage-guided stereotactic body radiation therapy for localized prostate cancer. Tumori2011;97 (1):43–48
16.
BolziccoGFavrettoMSSatarianoNScreminETamboneCTascaAA single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol2013;13 (1):49
17.
ChenLNSuySUhmSStereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol2013;8 (1):58
18.
KatzAJSantoroMDiblasioFAshleyRStereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol2013;8 (1):118
19.
OliaiCLancianoRSprandioBStereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol2013;2 (1):63–70
20.
KatzAKangJStereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol2014;9 (1):1
21.
LeeYHSonSHYoonSCStereotactic body radiotherapy for prostate cancer: a preliminary report. Asia Pac J Clin Oncol2014;10 (2):e46–e53
22.
RayMEThamesHDLevyLBPSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys2006;64 (4):1140–1150
23.
KingCRFreemanDKaplanIStereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol2013;109 (2):217–221
24.
AsbellSOKrallJMPilepichMVElective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys1988;15 (6):1307–1316
25.
LawtonCADeSilvioMRoachMIIIAn update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys2007;69 (3):646–655
26.
PommierPChabaudSLagrangeJLIs there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol2007;25 (34):5366–5373
27.
JuAWWangHOermannEKHypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol2013;8 (1):30
28.
RoachMIIIBaeKSpeightJShort-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol2008;26 (4):585–591
29.
BollaMVan TienhovenGWardePExternal irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol2010;11 (11):1066–1073
30.
JonesCUHuntDMcGowanDGRadiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med2011;365 (2):107–118
31.
KubanDATuckerSLDongLLong-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008;70 (1):67–74
32.
PeetersSTHeemsbergenWDKoperPCDose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006;24 (13):1990–1996
33.
MohlerJLKantoffPWArmstrongAJet al;National Comprehensive Cancer Network. Prostate cancer, version 2.2014. J Natl Compr Canc Netw2014;12 (5):686–718
34.
AlongiFCozziLArcangeliSLinac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol2013;8 (1):171
35.
ScorsettiMAlongiFClericiEStereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. J Cancer Res Clin Oncol2014;140 (10):1795–1800
36.
TanTJSivaSForoudiFGillSStereotactic body radiotherapy for primary prostate cancer: a systematic review. J Med Imaging Radiat Oncol2014;58 (5):601–611
